# Galunisertib Combined With Capecitabine in Advanced CRC With PM

> **NCT05700656** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 31 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** Galunisertib plus capecitabine

## Key facts

- **NCT ID:** NCT05700656
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-28
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05700656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05700656, "Galunisertib Combined With Capecitabine in Advanced CRC With PM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05700656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*